ArticlePharmaceutics2021
Development of Novel Peptides for the Antimicrobial Combination Therapy against Carbapenem-Resistant
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Antimicrobial Peptides Based on the TisB Toxin: Toward Enhanced Activity and Synergy with Antibiotics.ACS omega · 2026Article
- Enhanced antibacterial activity of antimicrobial peptide-antibiotic combinations against multidrug-resistant bacteria.FEMS microbes · 2026Review
- The antimicrobial peptide Cec4 has therapeutic potential against clinical carbapenem-resistantMicrobiology spectrum · 2025Article
- Antimicrobial Peptide Octoprohibitin-Encapsulated Chitosan Nanoparticles Enhanced Antibacterial Activity againstPharmaceutics · 2024Article
- Investigating the Effectiveness of Ceragenins againstInternational journal of molecular sciences · 2024Article
- Antibiotics-free compounds for managing carbapenem-resistant bacteria; a narrative review.Frontiers in pharmacology · 2024Review
- An Update on the Therapeutic Potential of Antimicrobial Peptides againstPharmaceuticals (Basel, Switzerland) · 2023Review
- Characterization of the Antimicrobial Activities ofPharmaceutics · 2023Article
- Antimicrobial Peptide Cec4 Eradicates Multidrug-ResistantDrug design, development and therapy · 2023Article
- Rhamnetin, a Natural Flavonoid, Ameliorates Organ Damage in a Mouse Model of Carbapenem-ResistantInternational journal of molecular sciences · 2022Article
- Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2022Review
- Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options.Infectious diseases and therapy · 2022Review
- Multidrug resistance crisis during COVID-19 pandemic: Role of anti-microbial peptides as next-generation therapeutics.Colloids and surfaces. B, Biointerfaces · 2022Review
- Antiseptic 9-Meric Peptide with Potency against Carbapenem-ResistantInternational journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.